Literature DB >> 21568886

Aluminum vaccine adjuvants: are they safe?

L Tomljenovic1, C A Shaw.   

Abstract

Aluminum is an experimentally demonstrated neurotoxin and the most commonly used vaccine adjuvant. Despite almost 90 years of widespread use of aluminum adjuvants, medical science's understanding about their mechanisms of action is still remarkably poor. There is also a concerning scarcity of data on toxicology and pharmacokinetics of these compounds. In spite of this, the notion that aluminum in vaccines is safe appears to be widely accepted. Experimental research, however, clearly shows that aluminum adjuvants have a potential to induce serious immunological disorders in humans. In particular, aluminum in adjuvant form carries a risk for autoimmunity, long-term brain inflammation and associated neurological complications and may thus have profound and widespread adverse health consequences. In our opinion, the possibility that vaccine benefits may have been overrated and the risk of potential adverse effects underestimated, has not been rigorously evaluated in the medical and scientific community. We hope that the present paper will provide a framework for a much needed and long overdue assessment of this highly contentious medical issue.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21568886     DOI: 10.2174/092986711795933740

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  38 in total

Review 1.  Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts.

Authors:  Calvin C Willhite; Nataliya A Karyakina; Robert A Yokel; Nagarajkumar Yenugadhati; Thomas M Wisniewski; Ian M F Arnold; Franco Momoli; Daniel Krewski
Journal:  Crit Rev Toxicol       Date:  2014-10       Impact factor: 5.635

Review 2.  Adjuvants and lymphoma risk as part of the ASIA spectrum.

Authors:  Dana Butnaru; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

3.  Rational incorporation of molecular adjuvants into a hybrid nanoparticle-based nicotine vaccine for immunotherapy against nicotine addiction.

Authors:  Zongmin Zhao; Brian Harris; Yun Hu; Theresa Harmon; Paul R Pentel; Marion Ehrich; Chenming Zhang
Journal:  Biomaterials       Date:  2017-11-20       Impact factor: 12.479

4.  Macrophagic myofasciitis: characterization and pathophysiology.

Authors:  R K Gherardi; F J Authier
Journal:  Lupus       Date:  2012-02       Impact factor: 2.911

5.  Chronic kidney disease of unknown etiology and the effect of multiple-ion interactions.

Authors:  M W C Dharma-Wardana
Journal:  Environ Geochem Health       Date:  2017-09-01       Impact factor: 4.609

6.  The next-generation nicotine vaccine: a novel and potent hybrid nanoparticle-based nicotine vaccine.

Authors:  Yun Hu; Daniel Smith; Evan Frazier; Reece Hoerle; Marion Ehrich; Chenming Zhang
Journal:  Biomaterials       Date:  2016-08-18       Impact factor: 12.479

Review 7.  Aluminum in the central nervous system (CNS): toxicity in humans and animals, vaccine adjuvants, and autoimmunity.

Authors:  C A Shaw; L Tomljenovic
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

8.  Aluminum-Induced Synaptic Plasticity Impairment via PI3K-Akt-mTOR Signaling Pathway.

Authors:  Huan Li; Xingli Xue; Liang Li; Yaqin Li; Yanni Wang; Tao Huang; Yanhong Wang; Huaxing Meng; Baolong Pan; Qiao Niu
Journal:  Neurotox Res       Date:  2020-01-23       Impact factor: 3.911

Review 9.  Applications of chemokines as adjuvants for vaccine immunotherapy.

Authors:  Teena Mohan; Wandi Zhu; Ye Wang; Bao-Zhong Wang
Journal:  Immunobiology       Date:  2017-12-08       Impact factor: 3.144

10.  Autoimmune/autoinflammatory syndrome induced by adjuvants (ASIA syndrome) in commercial sheep.

Authors:  Lluís Luján; Marta Pérez; Eider Salazar; Neila Álvarez; Marina Gimeno; Pedro Pinczowski; Silvia Irusta; Jesús Santamaría; Nerea Insausti; Yerzol Cortés; Luis Figueras; Isabel Cuartielles; Miguel Vila; Enrique Fantova; José Luis Gracia Chapullé
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.